{
    "clinical_study": {
        "@rank": "131002", 
        "acronym": "POST-TURP", 
        "arm_group": [
            {
                "arm_group_label": "Solifenacin group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate superiority of the solifenacin succinate\n      (treatment) over the placebo (control) based on the change from the baseline in the mean\n      number of urgency episodes per 24 hours after 2 weeks."
        }, 
        "brief_title": "Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Overactive Bladder", 
            "Benign Prostate Hyperplasia", 
            "Transurethral Resection of Prostate", 
            "Photoselective Vaporization Prostatectomy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Hyperplasia", 
                "Hyperplasia", 
                "Urinary Bladder, Overactive"
            ]
        }, 
        "detailed_description": {
            "textblock": "The BPH (benign prostate hyperplasia) patients who have OAB (overactive bladder) after TURP\n      (trans-urethral resection of prostate) or PVP (photoselective vaporization of prostate) will\n      participate in this study.  The subjects will be randomized 1:1 to the solifenacin succinate\n      group or to the placebo treatment group.  The subjects shall take investigational product\n      each night before sleeping from for four weeks and complete voiding diary.  At Week-2 and\n      Week-4 of the treatment, the subjects will be asked to complete the following activities:\n      physical exam, vital signs test, IPSS, OABSS, post-void residual (PVR) test, and\n      uroflowmetry, and will be asked to answer the BSW, (Benefit, Satisfaction and Willingness to\n      Continue Questions) questionnaire."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Screening\n\n               -  Patients who are willing and able to accurately complete the voiding diary,\n                  IPSS, and OABSS\n\n               -  Patients who have been diagnosed with BPH and are scheduled to receive TURP or\n                  PVP\n\n          -  Randomization (after TURP or PVP)\n\n               -  Patients who have been diagnosed with OAB by the investigators\n\n               -  Patients who underwent catheter removal 5\u00b12 days beforehand and will have more\n                  than an average of three urgency episodes per 24 hrs and more than an average of\n                  eight micturitions per 24 hrs in a row before Visit 3, as recorded in the\n                  voiding diary\n\n               -  Patients who will score more than 5 in questions 2, 4, and 7, which are on the\n                  storage symptoms in IPSS\n\n               -  Patients who will score more than 4 in question 3 and more than 5 in the OABSS\n\n               -  Patients who have not been treated with any medication for overactive bladder\n                  (OAB) symptoms 14 days before the randomization\n\n        Exclusion Criteria:\n\n          -  Screening\n\n               -  Patients who have been diagnosed with prostate cancer or bladder cancer and who\n                  have a present or resolved malignant disease in any pelvic organ\n\n               -  Patients who have neurological diseases that affect micturition and can cause\n                  neurogenic bladder disease such as multiple sclerosis, Parkinson's disease,\n                  severe cerebral arteriosclerosis, dementia, stroke, or myelitis\n\n               -  Patients who have had serious adverse events or are hypersensitive to\n                  anticholinergics\n\n               -  Patients who have a severe gastrointestinal obstruction disease such as toxin\n                  megacolon, ulcerative colitis, intestinal atonia, paralytic ileus, and gastric\n                  retention\n\n               -  Patients who have been diagnosed with severe myasthenia\n\n               -  Patients who have been diagnosed with narrow-angle glaucoma\n\n               -  Patients who have serious hepatic impairment (child class C)\n\n               -  Patients who are being treated with a CYP3A4 inhibitor (e.g., Ketoconazole)\n\n               -  Patients who have severe renal impairment or who are undergoing hemodialysis\n\n               -  Patients who have diabetic neuropathy\n\n               -  Patients who have a significant urinogenital disease such as UTI, interstitial\n                  cystitis, urothelial tumor, bladder stone, or urinary retention\n\n               -  Patients with rare hereditary problems of galactose intolerance, the Lapp\n                  lactase deficiency or glucose-galactose malabsorption\n\n               -  Patients who have another medical or psychiatric condition that will make them\n                  inappropriate for participate in this study in the opinion of the investigators\n\n               -  Patients who have participated in other clinical trials within 30 days before\n                  the screening visit\n\n          -  Randomization\n\n               -  Patients who have been diagnosed with clinically significant bladder outlet\n                  obstruction by investigators\n\n               -  Patients whose PVR is greater than 100 mL\n\n               -  Patients who have been diagnosed with prostate cancer or bladder cancer and who\n                  have a present or resolved malignant disease in any pelvic organ\n\n               -  Patients who have neurological diseases that affect micturition and can cause\n                  neurogenic bladder disease such as multiple sclerosis, Parkinson's disease,\n                  severe cerebral arteriosclerosis, dementia, stroke, or myelitis\n\n               -  Patients who have had serious adverse events or are hypersensitive to\n                  anticholinergics\n\n               -  Patients who have a severe gastrointestinal obstruction disease such as toxin\n                  megacolon, ulcerative colitis, intestinal atonia, paralytic ileus, and gastric\n                  retention\n\n               -  Patients who have been diagnosed with severe myasthenia\n\n               -  Patients who have been diagnosed with narrow-angle glaucoma\n\n               -  Patients who have serious hepatic impairment (child class C)\n\n               -  Patients who are being treated with a CYP3A4 inhibitor (e.g., Ketoconazole)\n\n               -  Patients who have severe renal impairment or who are undergoing hemodialysis\n\n               -  Patients who experienced severe side effects after their operation\n\n               -  Patients who have diabetic neuropathy\n\n               -  Patients who have a significant urinogenital disease such as UTI, interstitial\n                  cystitis, urothelial tumor, bladder stone, or urinary retention\n\n               -  Patients with rare hereditary problems of galactose intolerance, the Lapp\n                  lactase deficiency or glucose-galactose malabsorption\n\n               -  Patients who have another medical or psychiatric condition that will make them\n                  inappropriate for participate in this study in the opinion of the investigators\n\n               -  Patients who have participated in other clinical trials within 30 days before\n                  the screening visit"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747577", 
            "org_study_id": "VC-OAB-12-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Solifenacin group", 
                "description": "Oral", 
                "intervention_name": "Solifenacin Succinate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "YM905", 
                    "Vesicare\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Placebo group", 
                "description": "Oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Muscarine antagonist", 
            "Prostatectomy", 
            "Uroflowmetry"
        ], 
        "lastchanged_date": "January 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Soul", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, and Phase IV Study of Efficacy and Safety of Solifenacin Succinate in Patients With Overactive Bladder After TURP or PVP", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change from the baseline in the number of urgency episodes per 24 hrs in the voiding diary at Week 2", 
            "safety_issue": "No", 
            "time_frame": "Baseline and at week 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747577"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean change from the baseline in the number of urgency episodes per 24 hrs in the voiding diary at Week 4", 
                "safety_issue": "No", 
                "time_frame": "Baseline and at week 4"
            }, 
            {
                "description": "IPSS: International Prostate Symptom Score", 
                "measure": "Change from baseline in IPSS total score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at week 2 and at week 4"
            }, 
            {
                "measure": "Changes from baseline in IPSS storage subscale score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at week 2 and at week 4"
            }, 
            {
                "measure": "Changes from baseline in IPSS voiding subscale score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at week 2 and at week 4"
            }, 
            {
                "measure": "Changes from baseline in individual IPSS scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at week 2 and at week 4"
            }, 
            {
                "description": "QOL: Quality of Life", 
                "measure": "Changes from baseline in IPSS QOL", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at week 2 and at week 4"
            }, 
            {
                "description": "OABSS: OverActive Bladder Sympton Score", 
                "measure": "Changes from baseline in OABSS total score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at week 2 and at week 4"
            }, 
            {
                "measure": "Change from baseline in average number of micturitions per 24 hrs for three days as recorded in the voiding diary", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at week 2 and at week 4"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, physical exam, and vital signs", 
                "safety_issue": "No", 
                "time_frame": "For 4 weeks of the treatment"
            }, 
            {
                "description": "Measured by ultrasound or bladder scan", 
                "measure": "Urinal post voiding residual volume", 
                "safety_issue": "Yes", 
                "time_frame": "Before treatment at week 2 and at week 4"
            }, 
            {
                "description": "Assessment using uroflowmetry", 
                "measure": "Maximum flow rate of the urine", 
                "safety_issue": "Yes", 
                "time_frame": "Before treatment at week 2 and at week 4"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Korea, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}